Intralesional Kenalog for Alopecia Areata in Ehlers-Danlos Syndrome
Intralesional triamcinolone acetonide (Kenalog) injections can be used for alopecia areata in patients with Ehlers-Danlos syndrome, but require heightened caution due to the increased risk of skin atrophy and poor wound healing inherent to this connective tissue disorder.
Primary Considerations for EDS Patients
The main concern with intralesional corticosteroid injections in Ehlers-Danlos syndrome relates to the fragile skin and abnormal collagen structure characteristic of this condition. While neither the British Association of Dermatologists guidelines 1 nor the FDA labeling 2 specifically contraindicate use in EDS, several factors warrant careful consideration:
Atrophy Risk is Amplified
- Patients with EDS have inherently fragile skin with defective collagen, making them more susceptible to corticosteroid-induced atrophy 2
- The FDA label explicitly warns that "atrophy of subcutaneous fat may occur if the injection is not properly given" 2
- In normal patients, atrophy is already a recognized side effect of intralesional corticosteroids 1, and this risk is magnified in EDS where tissue integrity is already compromised
Technical Modifications Required
- Use the lowest effective concentration: Start with 2.5 mg/mL triamcinolone acetonide rather than higher concentrations 3
- Evidence shows 2.5 mg/mL can be effective with a step-up approach if needed, reducing adverse effects compared to 10 mg/mL 3
- Inject precisely into the upper subcutis just beneath the dermis using small volumes (0.05-0.1 mL per injection site) 1
- Avoid injecting into surrounding tissues, as this increases atrophy risk 2
Treatment Protocol for EDS Patients
Initial Approach
- Begin with 2.5 mg/mL triamcinolone acetonide administered monthly 3, 4
- Limit injection volume to 0.05-0.1 mL per site to minimize tissue trauma 1
- Space injections appropriately across the affected area rather than concentrating in one location 1
Monitoring Strategy
- Examine closely for early signs of atrophy or telangiectasia at each visit before proceeding with subsequent injections 3
- If atrophy develops, discontinue treatment immediately and avoid treating those areas 5
- Consider limiting to 3 treatment sessions initially, as efficacy is typically evident by 12 weeks 1, 6
Expected Outcomes
- Approximately 52-62% of patients achieve significant hair regrowth with intralesional triamcinolone 1
- Response is better in patients with fewer than five patches less than 3 cm in diameter 1
- Hair regrowth typically appears as tufts at injection sites, with effects lasting approximately 9 months 1
Critical Pitfalls to Avoid
- Never inject into the dermis itself or too superficially, as this dramatically increases atrophy risk in already-fragile EDS skin 2
- Do not use concentrations higher than 5 mg/mL initially in EDS patients, despite some protocols using 10 mg/mL in standard populations 3, 4
- Avoid treating areas that show any depression or atrophy from previous injections, as this will not reverse and may worsen 5
- Be aware that rare anaphylaxis to triamcinolone acetonide can occur, even after multiple uneventful injections 7
Alternative Considerations
If concern about atrophy is prohibitive, consider:
- Topical clobetasol propionate 0.05% under occlusion, which showed 18% long-term regrowth in severe cases 1
- Intralesional vitamin D3 injections, which showed comparable efficacy to triamcinolone with better tolerability profiles 8
- For extensive disease (SALT score ≥20), systemic JAK inhibitors like baricitinib are now EMA-approved and avoid local tissue complications 9